Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Takeover/Way Undervalued
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by Hockeyzon Sep 06, 2016 1:27am
102 Views
Post# 25208958

RE:RE:RE:RE:RE:RE:RE:RE:RE:Takeover/Way Undervalued

RE:RE:RE:RE:RE:RE:RE:RE:RE:Takeover/Way Undervaluedhttps://seekingalpha.com/article/3999508-concordia-q2-review-series-misfortunes-mismanagement?li_source=LI&li_medium=liftigniter-widget

Yes, you are quite close to the 5.96X net debt to EBITDA for 2017 in the article above, near the end.  2018 at 5.43X, 2019 at 4.75X and 2020 at 4.11X.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities